Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Bevacizumab 55Cetuximab 52Fluorouracil 45Oxaliplatin 39Leucovorin 38pembrolizumab 34Specimen Handling 29Irinotecan 24Magnetic Resonance Spectroscopy 18Biopsy 18Nivolumab 17Capecitabine 14trifluridine tipiracil drug combination 13HMPL-013 13Folfox protocol 13Panitumumab 12Gemcitabine 12Cisplatin 12Carboplatin 11encorafenib 9balstilimab 9Standard of Care 9Pemetrexed 9IFL protocol 9Trifluridine 8Paclitaxel 8Early Intervention, Educational 8130-nm albumin-bound paclitaxel 8fludarabine 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Adjuvants, Immunologic × 90 days × Clear all
NCT06130826 2026-06-03

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

City of Hope Medical Center

Phase 1 Suspended
24 enrolled
BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡